NCT03317093View on ClinicalTrials.gov

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

October 21, 2019

Study Completion Date

November 4, 2019

Conditions
Inflamed MeningesSuspected MeningitisVentriculitis
Interventions
DRUG

Ceftobiprole Medocaril

1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0

OTHER

Blood samples and cerebrospinal fluid

Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.

Trial Locations (1)

21079

CHU Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT03317093 - Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device | Biotech Hunter | Biotech Hunter